Published in Future Oncol on March 23, 2015
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One (2016) 1.44
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep (2016) 1.03
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother (2016) 0.89
Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther (2015) 0.81
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. Medicine (Baltimore) (2016) 0.78
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials. Medicine (Baltimore) (2016) 0.78
Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheum Dis Clin North Am (2016) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov (2016) 0.75
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer (2017) 0.75
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. Front Immunol (2015) 0.75
Domain-swapped T cell receptors improve the safety of TCR gene therapy. Elife (2016) 0.75
Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients? Onco Targets Ther (2017) 0.75
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report. Medicine (Baltimore) (2016) 0.75
Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol (2017) 0.75
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer (2012) 1.87
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res (2007) 1.60
Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett (2008) 1.53
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One (2010) 1.40
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res (2008) 1.31
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res (2007) 1.07
Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) (2014) 1.05
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res (2012) 1.04
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist (2012) 1.04
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist (2013) 0.99
Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer (2010) 0.93
Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature. J Gastrointest Cancer (2012) 0.90
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs (2010) 0.87
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther (2011) 0.87
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB J (2013) 0.86
WT1 regulates angiogenesis in Ewing Sarcoma. Oncotarget (2014) 0.82
Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells. Cancer Biol Ther (2013) 0.80
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol (2014) 0.77
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med (2014) 0.77
Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res (2016) 0.75
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. Am J Surg Pathol (2017) 0.75